<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00063583</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DK063017-01</org_study_id>
    <secondary_id>R01DK063017</secondary_id>
    <nct_id>NCT00063583</nct_id>
    <nct_alias>NCT00105391</nct_alias>
  </id_info>
  <brief_title>Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes</brief_title>
  <official_title>Pirfenidone: A Novel Anti-Scarring Therapy for Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharma, Kumar, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sharma, Kumar, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a new investigational drug, pirfenidone,
      will be an effective therapy for diabetic patients with kidney dysfunction. Our hypothesis is
      that administration of pirfenidone to type 1 and type 2 diabetic patients with advanced
      kidney disease will lead to preservation of kidney function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic kidney disease is the leading cause of new cases of kidney failure in the United
      States. In the kidneys of diabetic patients, there is accumulation of protein that leads to
      the formation of scar tissue and poor kidney function. Because of this many patients
      eventually require dialysis or kidney transplantation. A new investigational drug,
      pirfenidone, has been shown to be beneficial in a number of diseases in which scar formation
      leads to disease progression. It is our goal to examine whether pirfenidone is effective at
      stabilizing or reducing progressive diabetic kidney dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint will be the change in renal function from baseline to the end of the study period (12 months).</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% change in urine albumin excretion from baseline to end of study period.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change in levels of TGF-b1 in urine, plasma and serum from baseline to end of study period.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>â€¢ Determine the relationship between % change in TGF-b1 levels and the change in GFR</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pirfenidone 1200 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pirfenidone will be administered at a dose of 1200 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pirfenidone 2400 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pirfenidone will be administered at 2400 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Pirfenidone 1200 mg/day</arm_group_label>
    <arm_group_label>Pirfenidone 2400 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  Type 1 or type 2 diabetes

          -  Males and females greater than or equal to 18 years.

          -  Abnormal kidney function determined by glomerular filtration rate

          -  History of proteinuria

          -  Blood pressure controlled to &lt;140/90 on anti-hypertensive medication

        Exclusion

          -  Cancer, liver disease, hepatitis, HIV+

          -  History of heart attack, unstable angina, stroke or peptic ulcer in the past 6 months

          -  Pregnant or planning to become pregnant during the study period

          -  Other known kidney disease besides diabetic nephropathy

          -  Expect to begin dialysis or receive a kidney transplant within 1 year of study
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kumar Sharma, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Diabetic Kidney Disease at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR, Kurnik PB, Weisberg LS. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes. 1997 May;46(5):854-9.</citation>
    <PMID>9133555</PMID>
  </reference>
  <reference>
    <citation>Shimizu F, Fukagawa M, Yamauchi S, Taniyama M, Komemushi S, Margolin SB, Kurokawa K: Pirfenidone prevents the progression of irreversible glomerular sclerotic lesions in rats. Nephrology 3:315-322, 1997</citation>
  </reference>
  <reference>
    <citation>Shimizu T, Fukagawa M, Kuroda T, Hata S, Iwasaki Y, Nemoto M, Shirai K, Yamauchi S, Margolin SB, Shimizu F, Kurokawa K. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl. 1997 Dec;63:S239-43.</citation>
    <PMID>9407470</PMID>
  </reference>
  <reference>
    <citation>Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999 Oct;291(1):367-73.</citation>
    <PMID>10490926</PMID>
  </reference>
  <reference>
    <citation>McGowan T, Dunn SR, Sharma K: Treatment of db/db mice with pirfenidone leads to improved histology and serum creatinine. J Am Soc Nephrology 11:A2814, 2000</citation>
  </reference>
  <reference>
    <citation>Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1061-9.</citation>
    <PMID>10194146</PMID>
  </reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2003</study_first_submitted>
  <study_first_submitted_qc>July 1, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2003</study_first_posted>
  <last_update_submitted>November 3, 2009</last_update_submitted>
  <last_update_submitted_qc>November 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kumar Sharma</name_title>
    <organization>UCSD</organization>
  </responsible_party>
  <keyword>Kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

